98%
921
2 minutes
20
The synthesis of the first series of a new class of nucleoside phosphonate analogues is described. Addition of a carboxyl group at the α position of carbocyclic nucleoside phosphonate analogues leads to a novel class of potent HIV reverse transcriptase (RT) inhibitors, α-carboxy nucleoside phosphonates (α-CNPs). Key steps in the synthesis of the compounds are Rh-catalyzed O-H insertion and Pd-catalyzed allylation reactions. In cell-free assays, the final products are markedly inhibitory against HIV RT and do not require phosphorylation to exhibit anti-RT activity, which indicates that the α-carboxyphosphonate function is efficiently recognized by HIV RT as a triphosphate entity, an unprecedented property of nucleoside monophosph(on)ates.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/jo502549y | DOI Listing |
HIV Med
September 2025
Moscow Regional AIDS Center, Moscow Region, Kotelniki, Russia.
Objectives: This study aimed to evaluate the effectiveness of bictegravir (BIC)-based antiretroviral therapy (ART) against HIV-1 sub-subtype A6 viruses carrying the L74I polymorphic mutation in integrase.
Methods: A total of 100 ART-naive people living with HIV from the Moscow Regional AIDS Center were enrolled between May and July 2023. HIV-1 subtypes and baseline drug resistance mutations were analysed prior to treatment initiation.
Lancet HIV
September 2025
Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA. Electronic address:
Background: Patients on second-line protease inhibitor-based regimens in low-income and middle-income countries have high rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance, but access to testing is scarce. We aimed to assess the efficacy of combination oral bictegravir, emtricitabine, and tenofovir alafenamide in this population.
Methods: In this open-label non-inferiority trial conducted in Port-au-Prince, Haiti, adults (aged 18 years or older) with viral suppression (HIV-1 RNA <200 copies per mL) on second-line regimens including ritonavir-boosted protease inhibitors and two NRTIs were randomised (1:1) using a computer-generated random-number list.
J Med Virol
September 2025
Unit of Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.
We investigated factors associated with HBV-rebound in people with HIV (PWH) with chronic HBV (CHBV) under HBV-active antiretroviral therapy (ART): emtricitabine (FTC)+tenofovir alafenamide (TAF) or 3TC/FTC+ tenofovir disoproxil fumarate (TDF) regimen. The present study included PWH/CHBV followed as outpatients from October 2008 to August 2023 at San Raffaele Hospital, Milan, Italy. The baseline evaluation was the date of first negative HBV-DNA (< 10 IU/mL) after the first positive result before HBV active ART.
View Article and Find Full Text PDFIntroduction: Older adults with HIV, particularly those ≥ 50 years of age, face unique health challenges due to a higher prevalence of comorbidities and polypharmacy, which can impact medication adherence and increase the risk of adverse events. We assessed the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH) ≥ 50 years of age across treatment-naïve and virologically suppressed cohorts over a long-term follow-up.
Methods: This post hoc analysis included participants ≥ 50 and < 50 years of age from six phase 3 trials of B/F/TAF, comprising 2 treatment-naïve studies and 4 virologically suppressed studies.
J Org Chem
September 2025
Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Katsushika-ku, Tokyo 125-8585, Japan.
Nucleoside 3'--phosphonothioate monoesters possess two nucleophilic atoms, i.e., oxygen and sulfur atoms; therefore, their chemoselectivity must be controlled during condensation with a 5'-hydroxy group for the synthesis of oligonucleotides.
View Article and Find Full Text PDF